GlaxoSmithKline has signed up San Francisco-based incubator QB3@953 to seek out and facilitate collaborations that will translate early drug target concepts into medicines.
Under the agreement, QB3@953 will work hand-in-hand with GSK to identify innovators exploring targets with “therapeutic potential and a defined clinical hypothesis,” giving the drug giant a channel for forming new alliances.
The move combines the resources and capabilities of GSK with the equipment, lab space and services available at QB3@953, striving to create an optimal environment for scientists to carry out their work and advance their research through developmental stages.
“This is about finding innovators with great biology and connecting them with GSK’s tremendous drug discovery and development capabilities,” explained Douglas Crawford, associate director of QB3 and founder of QB3@953.
QB3@953 is a full-service incubator for life science startups, created by QB3, a University of California research institute and biotech accelerator.
